Disease modifying therapies in multiple sclerosis: Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines [RETIRED]
Open accessThe DOI matches its Crossref record; 105 of the 105 references it cites were found in a registry or an index.
Abstract
Overview.Clinical types of MS.MS is a chronic recurrent inflammatory disorder of the CNS.The disease results in injury to the myelin sheaths, the oligodendrocytes, and, to a lesser extent, the axons and nerve cells themselves.[1][2][3][4][5] The symptoms of MS vary, depending in part on the location of plaques within the CNS.Common symptoms include sensory disturbances in the limbs, optic nerve dysfunction, pyramidal tract dysfunction, bladder or bowel dysfunction, sexual dysfunction, ataxia, and diplopia.5 Four different clinical courses of MS have been defined.6 The first, relapsing-remitting MS (RRMS), is characterized by self-limited attacks of neurologic dysfunction.These attacks develop acutely, evolving over days to weeks.Over the next several weeks to months, most patients experience a recovery of function that is often (but not always) complete.Between attacks the patient is neurologically and symptomatically stable.The second clinical course, secondary progressive MS (SPMS), begins as RRMS, but at some point the attack rate is reduced and the course becomes characterized by a steady deterioration in function unrelated to acute attacks.The third clinical type, primary progressive MS (PPMS), is characterized by a steady decline in function from the beginning without acute attacks.The fourth type, progressive-relapsing MS (PRMS), also begins with a progressive course although these patients also experience occasional attacks.Outcome measures in MS clinical trials.Evaluation of the relative effectiveness of different therapies requires consideration of which outcome measure or measures are relevant to the goals of therapy.Clearly, the most important therapeutic aim of any disease-modifying treatment of MS is to prevent or postpone long-term disability.However, long-term disability in MS often evolves slowly over many years.[1][2][3] Clinical trials, by contrast, study patients for only short periods of time (2 or 3 years) and, therefore, use only short-term outcome measures to assess efficacy.As a result, it is important to validate any short-term measure by its correlation with the actual patient outcome many years later.For a discussion of these issues, interested readers should consult the full-length assessment on the Neurology Web site at www.neurology.org.Scope of this guideline.The purpose of this assessment is to consider the clinical utility of these disease-modifying agents including the anti-inflammatory, immunomodulatory, and immunosuppressive treatments that are currently available.Symptomatic and reparative therapies will not be considered. Before considering the evidence from individualAdditional material related to this article can be found on the Neurology Web site.Go to www.neurology.org and scroll down the Table of Contents for the January 22 issue to find the title link for this article.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Power Analysis for the Behavioral Sciences
Muller, K. (1989) · Technometrics · doi:10.1080/00401706.1989.10488618 · Cited by 99,167
Statistical power analysis for the behavioral sciences
(1990) · Computers, Environment and Urban Systems · doi:10.1016/0198-9715(90)90050-4 · Cited by 65,269
Statistical Power Analysis for the Behavioral Sciences (2nd ed.).
Lachenbruch, P. A., & Cohen, J. (1989) · Journal of the American Statistical Association · doi:10.2307/2290095 · Cited by 37,395
New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
Poser, C. M., Paty, D. W., Scheinberg, L., McDonald, W. I., Davis, F. A., Ebers, G. C., Johnson, K. P., Sibley, W. A., Silberberg, D. H., & Tourtellotte, W. W. (1983) · Annals of Neurology · doi:10.1002/ana.410130302 · Cited by 7,384
Self-citationMcDonald, W. I., Compston, A., Edan, G., Goodkin, D., Hartung, H., Lublin, F. D., McFarland, H. F., Paty, D. W., Polman, C. H., Reingold, S. C., et al. (2001) · Annals of Neurology · doi:10.1002/ana.1032 · Cited by 6,969
Axonal transection in the lesions of multiple sclerosis
Trapp, B. D., Peterson, J., Ransohoff, R. M., Rudick, R., Mörk, S., & Bö, L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801293380502 · Cited by 4,029
Defining the clinical course of multiple sclerosis: Results of an international survey
Lublin, F. D., Reingold, S. C., & National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis* (1996) · Neurology · doi:10.1212/wnl.46.4.907 · Cited by 3,686
More powerful procedures for multiple significance testing
Hochberg, Y., & Benjamini, Y. (1990) · Statistics in Medicine · doi:10.1002/sim.4780090710 · Cited by 2,715
Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis
Jacobs, L. D., Cookfair, D. L., Rudick, R. A., Herndon, R. M., Richert, J. R., Salazar, A. M., Fischer, J. S., Goodkin, D. E., Granger, C. V., Simon, J. H., et al. (1996) · Annals of Neurology · doi:10.1002/ana.410390304 · Cited by 2,450
Cognitive dysfunction in multiple sclerosis.: I. Frequency, patterns, and prediction
Rao, S. M., Leo, G. J., Bernardin, L., & Unverzagt, F. (1991) · Neurology · doi:10.1212/wnl.41.5.685 · Cited by 2,110
Cited by
A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis
Lennon, V. A., Wingerchuk, D. M., Kryzer, T. J., Pittock, S. J., Lucchinetti, C. F., Fujihara, K., Nakashima, I., & Weinshenker, B. G. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17551-x · Cited by 3,239
Revised diagnostic criteria for neuromyelitis optica
Wingerchuk, D. M., Lennon, V. A., Pittock, S. J., Lucchinetti, C. F., & Weinshenker, B. G. (2006) · Neurology · doi:10.1212/01.wnl.0000216139.44259.74 · Cited by 2,574
IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel
Lennon, V. A., Kryzer, T. J., Pittock, S. J., Verkman, A. S., & Hinson, S. R. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050304 · Cited by 2,288
Cortical demyelination and diffuse white matter injury in multiple sclerosis
Kutzelnigg, A., Lucchinetti, C. F., Stadelmann, C., Brück, W., Rauschka, H., Bergmann, M., Schmidbauer, M., Parisi, J. E., & Lassmann, H. (2005) · Brain · doi:10.1093/brain/awh641 · Cited by 1,836
Multiple Sclerosis — The Plaque and Its Pathogenesis
Frohman, E. M., Racke, M. K., & Raine, C. S. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052130 · Cited by 1,740
Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis
Brinkmann, V., Billich, A., Baumruker, T., Heining, P., Schmouder, R., Francis, G., Aradhye, S., & Burtin, P. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3248 · Cited by 1,273
Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis
Kappos, L., Antel, J., Comi, G., Montalban, X., O'Connor, P., Polman, C. H., Haas, T., Korn, A. A., Karlsson, G., & Radue, E. W. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052643 · Cited by 1,054
Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802670 · Cited by 1,017
Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis
Chun, J., & Hartung, H.-P. (2010) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3181cbf825 · Cited by 796
Brain Abnormalities in Neuromyelitis Optica
Pittock, S. J., Lennon, V. A., Krecke, K., Wingerchuk, D. M., Lucchinetti, C. F., & Weinshenker, B. G. (2006) · Archives of Neurology · doi:10.1001/archneur.63.3.390 · Cited by 675
Randomized, comparative study of interferon β-1a treatment regimens in MS: The EVIDENCE Trial
Panitch, H., Goodin, D. S., Francis, G., Chang, P., Coyle, P. K., O’Connor, P., Monaghan, E., Li, D., & Weinshenker, B. (2002) · Neurology · doi:10.1212/01.wnl.0000034080.43681.da · Cited by 635
Rae-Grant, A., Day, G. S., Marrie, R. A., Rabinstein, A., Cree, B. A. C., Gronseth, G. S., Haboubi, M., Halper, J., Hosey, J. P., Jones, D. E., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000005347 · Cited by 595
Immunomodulatory effects of Vitamin D in multiple sclerosis
Correale, J., Ysrraelit, M. C., & Gaitan, M. I. (2009) · Brain · doi:10.1093/brain/awp033 · Cited by 538
Oral simvastatin treatment in relapsing-remitting multiple sclerosis
Vollmer, T., Key, L., Durkalski, V., Tyor, W., Corboy, J., Markovic-Plese, S., Preiningerova, J., Rizzo, M., & Singh, I. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16205-3 · Cited by 469
Interferon beta-1b in secondary progressive MS: Results from a 3-year controlled study
The North American Study Group on Interferon beta-1b in Secondary Progressive MS (2004) · Neurology · doi:10.1212/01.wnl.0000146958.77317.3e · Cited by 423
The benefits of exercise training in multiple sclerosis
Motl, R. W., & Pilutti, L. A. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.136 · Cited by 394
T‐helper 17 cells expand in multiple sclerosis and are inhibited by interferon‐β
Durelli, L., Conti, L., Clerico, M., Boselli, D., Contessa, G., Ripellino, P., Ferrero, B., Eid, P., & Novelli, F. (2009) · Annals of Neurology · doi:10.1002/ana.21652 · Cited by 375
Interferon-β mechanisms of action in multiple sclerosis
Dhib-Jalbut, S., & Marks, S. (2010) · Neurology · doi:10.1212/wnl.0b013e3181c97d99 · Cited by 298
Kapoor, R., Furby, J., Hayton, T., Smith, K. J., Altmann, D. R., Brenner, R., Chataway, J., Hughes, R. A., & Miller, D. H. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70131-9 · Cited by 268
Inflammation and therapeutic vaccination in CNS diseases
Weiner, H. L., & Selkoe, D. J. (2002) · Nature · doi:10.1038/nature01325 · Cited by 255
Cannabinoids and the immune system: Potential for the treatment of inflammatory diseases?
Croxford, J. L., & Yamamura, T. (2005) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2005.04.023 · Cited by 255
Treatment for spasmodic dysphonia: limitations of current approaches
Ludlow, C. L. (2009) · Current Opinion in Otolaryngology & Head and Neck Surgery · doi:10.1097/moo.0b013e32832aef6f · Cited by 84
Kallaur, A. P., Oliveira, S. R., Simão, A. N. C., Alfieri, D. F., Flauzino, T., Lopes, J., de Carvalho Jennings Pereira, W. L., de Meleck Proença, C., Borelli, S. D., Kaimen-Maciel, D. R., et al. (2017) · Molecular Neurobiology · doi:10.1007/s12035-016-9846-x · Cited by 75
Carmosino, M. J., Brousseau, K. M., Arciniegas, D. B., & Corboy, J. R. (2005) · Archives of Neurology · doi:10.1001/archneur.62.4.585 · Cited by 74
Early predictors of conversion to secondary progressive multiple sclerosis
Barzegar, M., Najdaghi, S., Afshari-Safavi, A., Nehzat, N., Mirmosayyeb, O., & Shaygannejad, V. (2021) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2021.103115 · Cited by 52
Remyelinating and neuroprotective treatments in multiple sclerosis
Stangel, M. (2004) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.13.4.331 · Cited by 22
The knowns and unknowns of cardiac autoimmunity in viral myocarditis
Mone, K., & Reddy, J. (2023) · Reviews in Medical Virology · doi:10.1002/rmv.2478 · Cited by 19
Metadata
- Venue
- Neurology
- Published
- 2002-01-22
- Volume
- 58
- Issue
- 2
- Pages
- 169-178
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2034432056
- Cited by
- 797
- References
- 105
- FWCI
- 36.54
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.